SCHEMBL17653241

SCHEMBL17653241

CC(C)CCc1nc(C(N)=O)c2cc(Br)ccc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 4/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 3/20 0.41
KDM4E B2RXH2 1/20 0.41
KMT2A Q03164 1/20 0.40
AAK1 Q2M2I8 1/20 0.40
DPP4 P27487 1/20 0.40
DHODH Q02127 2/20 0.39
MPO P05164 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.37
SYK P43405 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MCL1 Q07820 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.36
PSMB1 P20618 1/20 0.36
PSMB5 P28074 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17653194 0.90 DHODH (0.43) RXFP1ALDH1A1GAAKDM4EKMT2A
SCHEMBL17653345 0.85 AAK1 (0.39) RXFP1ALDH1A1GAAKDM4EAAK1
SCHEMBL17653132 0.85 L3MBTL1 (0.48) RXFP1ALDH1A1GAAKDM4EAAK1
SCHEMBL17653272 0.81 AAK1 (0.65) AAK1
SCHEMBL17653177 0.78 AAK1 (0.44) RXFP1ALDH1A1GAAKDM4EAAK1
SCHEMBL17653165 0.76 AAK1 (0.43) RXFP1ALDH1A1GAAKDM4EAAK1
SCHEMBL17653174 0.75 PDE10A (0.44) RXFP1ALDH1A1GAAKDM4EAAK1
SCHEMBL17653336 0.75 AAK1 (0.43) RXFP1ALDH1A1KDM4EKMT2AAAK1
SCHEMBL17653358 0.75 AAK1 (0.45) RXFP1ALDH1A1GAAKDM4EKMT2A
SCHEMBL19253001 0.73 AAK1 (0.39) RXFP1ALDH1A1GAAKDM4EAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-08-24 US disclosed
EP-3200797-A1 QUINAZOLINE-BASED KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-09 EP disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed
WO-2016053794-A1 QUINAZOLINE-BASED KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239249-A1 QUINAZOLINE-BASED KINASE INHIBITORS AAK1, ULK1, NCK1 RXFP1 4427/4885ALDH1A1 3926/4885GAA 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.